TY - JOUR AU - G. Manisha, AU - GS Sharma, AU - S. Raja Shekar, AU - T. Rama Rao, PY - 2022/05/01 Y2 - 2024/03/29 TI - Design and development of stealth liposomes for oral administration of poorly bioavailable drug: https://doi.org/10.54037/WJPS.2022.100501 JF - World Journal of Pharmaceutical Sciences JA - World J Pharm Sci VL - 10 IS - 05 SE - Research Article DO - UR - https://wjpsonline.com/index.php/wjps/article/view/design-development-stealth-liposomes SP - 44-51 AB - <p>The aim of the present study was to formulate Stealth Liposomes containing Curcumin which are formulated by combinations of Cholesterol, Distearoylphosphatidylcholine, hydrogenated soyphosphotidylcholine to treat rheumatoid arthritis. Turmeric&nbsp;and especially its most active compound&nbsp;curcumin&nbsp;have many scientifically-proven health benefits. It's a potent anti-inflammatory and help improve symptoms of Rheumatoid arthritis. Total 8 formulations were developed using Cholesterol, Distearoylphosphatidylcholine, hydrogenated soyphosphotidylcholine in various ratios by thin film hydration method &amp; evaluated for Entrapment Efficiency, SEM, particle size and shape, FTIR studies, invitro dissolution studies. From the invitro studies we can say that as the cholesterol ratio increases, drug release rate is increased upto particular ratio. Among all the fomulations, F7 formulation shows best drug release of 92.62% by the end of 24 hours whereas all the other formulations did not release the drug more than F7. So F7 formulation was choosen as optimized formulation.</p> ER -